Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

10.9%

7 terminated/withdrawn out of 64 trials

Success Rate

82.5%

-4.0% vs industry average

Late-Stage Pipeline

17%

11 trials in Phase 3/4

Results Transparency

18%

6 of 33 completed trials have results

Key Signals

7 recruiting6 with results

Enrollment Performance

Analytics

N/A

15(38.5%)

Phase 2

9(23.1%)

Phase 3

7(17.9%)

Phase 4

4(10.3%)

Phase 1

3(7.7%)

Early Phase 1

1(2.6%)

39Total

N/A(15)

Phase 2(9)

Phase 3(7)

Phase 4(4)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (64)

Showing 20 of 64 trials

NCT03674255Enrolling By Invitation

Echocardiography: Value and Accuracy at REst and STress

Role: collaborator

NCT06320535Phase 1Active Not Recruiting

A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™

Role: collaborator

NCT07491939Recruiting

Palliative and Supportive Care to Help People With Arthritis to Live Well (ENRICH)

Role: collaborator

NCT01616875Phase 2Completed

Bristol Bladder Trial

Role: lead

NCT06700018Recruiting

Flow Patterns and Stent Thrombosis

Role: collaborator

NCT07269483Not ApplicableRecruiting

A Study Assessing Adult Patients Referred to an NHS Sleep Service With Suspected Obstructive Sleep Apnoea. This Study Aims to Compare the Sunrise Wearable Diagnostic Device Performance and Potential Inclusion in a NHS Diagnostic Pathway With Oximetry and WatchPAT Which Are Currently Used.

Role: collaborator

NCT04817449Completed

Spectroscopy in Ovarian Cancer

Role: collaborator

NCT02300766Recruiting

Cerebellar Mutism Syndrome Study

Role: collaborator

NCT07183579Recruiting

Effective Dosing of Burosumab in XLH

Role: collaborator

NCT06531408Active Not Recruiting

Predicting Incidental Gallbladder Cancer